Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4036433

O=C(O)C(F)(F)F.O=c1[nH]cnc2cc(F)cc(O)c12

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.40
PDPK1 O15530 2/20 0.35
IP6K1 Q92551 1/20 0.35
IP6K3 Q96PC2 1/20 0.35
BCL2 P10415 1/20 0.34
MCL1 Q07820 1/20 0.34
SLC2A1 P11166 1/20 0.34
TEK Q02763 4/20 0.34
KDR P35968 2/20 0.34
EPHB4 P54760 2/20 0.34
EGFR P00533 1/20 0.34
PDGFRB P09619 1/20 0.34
KIT P10721 1/20 0.34
FGFR1 P11362 1/20 0.34
FLT1 P17948 1/20 0.34
POLB P06746 1/20 0.33
BCAT2 O15382 1/20 0.33
CHEK1 O14757 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4036436 0.76 PARP1 (0.38) PARP1PDPK1IP6K1IP6K3SLC2A1
SCHEMBL3176187 0.74 PARP1 (0.59) PARP1PDPK1IP6K1IP6K3CHEK1
SCHEMBL29717535 0.74 PARP1 (0.59) PARP1PDPK1IP6K1IP6K3CHEK1
SCHEMBL21178273 0.71 CHEK1 (0.47) PARP1PDPK1IP6K1BCL2MCL1
SCHEMBL1012534 0.68 ESR2 (0.52) PARP1PDPK1RAB9A
SCHEMBL30353912 0.68 PARP1 (0.44) PARP1PDPK1IP6K1IP6K3EGFR
SCHEMBL15710544 0.68 PARP1 (0.44) PARP1PDPK1IP6K1IP6K3EGFR
Quinazolinone SCHEMBL31483770 0.68 PARP1 (0.72) PARP1PDPK1IP6K1IP6K3SLC2A1
Quinazolinone SCHEMBL28036592 0.68 PARP1 (0.72) PARP1PDPK1IP6K1IP6K3SLC2A1
Hydrochloric Acid SCHEMBL28832520 0.67 ESR2 (0.51) PARP1PDPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1444211-B1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2009-01-21 EP disclosed
US-20070088044-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB 2007-04-19 US disclosed
US-20050054662-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2005-03-10 US disclosed
EP-1444211-A2 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS AstraZeneca AB (SE) 2004-08-11 EP disclosed
WO-2003040109-A2 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054662-A1 Quinazoline derivatives as antitumor agents ERBB2, ERBB3, ABL1 PARP1 895/4885PDPK1 262/4885IP6K1 1603/4885
US-20070088044-A1 Quinazoline derivatives as antitumor agents ERBB2, EGFR, ERBB4 PARP1 1062/4885PDPK1 372/4885IP6K1 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.